Omeveloxolone

PreclinicalSmall molecule

SScott Barbuto

Omeveloxolone is one of 2 small molecule programs targeting Fatigue. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Friedreich's AtaxiaRecruiting

Friedreich's AtaxiaPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Friedreich's Ataxia

#DrugCompanyPhaseTrials

Vatiquinone

PPTC Therapeutics

Phase 3

1 2

Omeveloxolone

SScott Barbuto

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Friedreich's Ataxia

NCT07444333

Clinical

Trials by Indication[1]

Friedreich's Ataxia1 trial

Cardiac Output and Fatigue in Friedreich's Ataxia

Recruiting·SScott Barbuto·Preclinical·NCT07444333·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Omeveloxolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omeveloxolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omeveloxolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Scott Barbuto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SScott Barbuto

Omeveloxolone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Friedreich's Ataxia1 trial

References

Drug Info

Quick Facts

Related News